CAPPED BONUS-ZERTIFIKAT - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 18:33:57 07/06/2024 BST | ||
| 59.13 EUR | +2.21% |
|
| Current month | +2.53% | ||
| 1 month | -19.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 59.13 | +2.21% |
| 06/06/24 | 57.85 | -0.53% |
| 05/06/24 | 58.16 | +0.28% |
| 04/06/24 | 58 | +1.05% |
| 03/06/24 | 57.4 | -0.47% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 06:33 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Citi
|
| WKN | KH5F1G |
| ISIN | DE000KH5F1G3 |
| Date issued | 27/04/2023 |
| Strike | 99 $ |
| Maturity | 20/06/2024 (12 Days) |
| Parity | 1 : 1 |
| Emission price | 76.37 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 86.86 € |
|---|---|
| Lowest since issue | 56.35 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.7
USD
Average target price
82.7
USD
Spread / Average Target
+27.82%
- Stock Market
- Certificates
- Certificat